Beckman.com is conducting maintenance on its shopping cart Friday, July 10th at 9 pm PST thru Sunday, July 12th at 10 pm PST. During this time, orders can still be placed by calling Client Services. We look forward to providing you an improved shopping experience.
What does targeting blood vessels have to do with immunotherapy?
Malignant tumors hijack the circulatory system by forming new blood vessels to sustain tumor growth in a process called angiogenesis. Newly targeted immunotherapies are geared towards interfering with pro-angiogenic signals from tumors, aiming to delay their growth and even cause them to shrink. Anti-angiogenic immunotherapy also prevents large tumors from metastasizing. Drugs which induce oxygen starvation primarily act through the vascular endothelial growth factor (VEGF) signaling pathway.1 Additional information on immunotherapy can be found in our resource center here.
1. R.R. Ramjiawan, et al., "Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?" Angiogenesis 20(2): 185-204, 2017.
Oops. The page you wanted could not be found, so we brought you to something similar. If you still can't find what you want, try searching our site instead.